Skip to main content

U.S. Business 'Pharma Bro’ Martin Shkreli loses appeals of conviction, sentence

Martin Shkreli was awarded seven-year prison term for defrauding investors in hedge funds he founded.

The Associated Press

A federal appeals court on Thursday upheld the conviction and seven-year prison term of Martin Shkreli, the former pharmaceutical executive known as “Pharma Bro,” for defrauding investors in hedge funds he founded.

The 2nd U.S. Circuit Court of Appeals in Manhattan rejected Mr. Shkreli’s argument that his trial judge instructed the jury incorrectly about securities fraud.

It also rejected his claim that the US$7.36-million he was ordered to forfeit was excessive, and could have been reduced because his investors made money.

Story continues below advertisement

“We’re obviously disappointed,” Mark Baker, a lawyer who argued Mr. Shkreli’s appeal, said in an interview. “We hoped we would achieve a better result.”

John Marzulli, a spokesman for U.S. Attorney Richard Donoghue declined to comment.

Mr. Shkreli, 36, is perhaps best known for raising the price of the anti-parasitic drug Daraprim by more than 5,000 per cent while serving as chief executive of Turing Pharmaceuticals, now known as Phoenixus AG.

His August 2017 conviction also covered a charge that he conspired to manipulate the stock price of Retrophin Inc., a biopharmaceutical company he founded in 2011 and which ousted him three years later.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter